[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100350557":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":62,"centralContacts":66,"locations":73,"responsibleParty":94,"collaborators":98,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":56,"eligibilityCriteria":106,"healthyVolunteers":103,"sex":107,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":56,"studyType":113,"phases":114,"briefSummary":116,"conditions":117,"keywords":56,"overallStatus":90,"whyStopped":56,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},{"fullName":5,"class":6},"Shandong University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Antineoplastic Drugs and Anti-infective Drugs","EXPERIMENTAL","Bortezomib;eltrombopag;imatinib;dasatinib, pegaspargase and anti-infective drugs administered at standard dose for children with hematological neoplasms.",[13,14,15,16,17,18,19],"Drug: Bortezomib","Drug: Eltrombopag","Drug: Imatinib","Drug: dasatinib","Drug: Pegaspargase","Drug: Anti-Infective Drugs","Drug: PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor",[21,28,34,40,46,52,57],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Bortezomib","bortezomib was administered follow the doctor's advice.",[9],[27],"Velcade",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Eltrombopag","eltrombopag was administered follow the doctor's advice.",[9],[33],"promacta",{"type":22,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"Imatinib","imatinib was administered follow the doctor's advice.",[9],[39],"Gleevec",{"type":22,"name":41,"description":42,"armGroupLabels":43,"otherNames":44},"dasatinib","dasatinib was administered follow the doctor's advice.",[9],[45],"sprycel",{"type":22,"name":47,"description":48,"armGroupLabels":49,"otherNames":50},"Pegaspargase","pegaspargase was administered follow the doctor's advice.",[9],[51],"Oncaspar",{"type":22,"name":53,"description":54,"armGroupLabels":55,"otherNames":56},"Anti-Infective Drugs","anti-infective drugs was administered follow the doctor's advice.",[9],null,{"type":22,"name":58,"description":48,"armGroupLabels":59,"otherNames":60},"PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor",[9],[61],"PEG-rhG-CSF",[63],{"name":64,"affiliation":5,"role":65},"Wei Zhao, Ph.D","PRINCIPAL_INVESTIGATOR",[67,71],{"name":64,"role":68,"phone":69,"phoneExt":56,"email":70},"CONTACT","86053188383308","zhao4wei2@hotmail.com",{"name":72,"role":68,"phone":69,"phoneExt":56,"email":70},"Yan H Shi, Ph.D",[74,88],{"facility":75,"status":76,"city":77,"state":78,"zip":79,"country":80,"countryCode":81,"cosmosGeoPoint":82,"geoPoint":87,"contacts":56},"Department of Pediatrics, the Affiliated Hospital of Xuzhou Medical University","COMPLETED","Xuzhou","Jiangsu","221000","China","CN",{"type":83,"coordinates":84},"Point",[85,86],117.28386,34.20442,{"lat":86,"lon":85},{"facility":89,"status":90,"city":91,"state":92,"zip":93,"country":80,"countryCode":81,"cosmosGeoPoint":56,"geoPoint":56,"contacts":56},"State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","RECRUITING","Tanjin","Tianjin Municipality","300020",{"type":95,"investigatorFullName":96,"investigatorTitle":97,"investigatorAffiliation":5,"oldNameTitle":56,"oldOrganization":56},"SPONSOR_INVESTIGATOR","Wei Zhao","Professor; Head of department of clinical pharmacy and pharmacology",[99],{"name":100,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","100350557","phase-4-dose-individualization-of-antineoplastic-drugs-and-anti-infective-drug-in-children-with-hematoplastic-disease-100350557",false,"NCT03844360","Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease","Inclusion Criteria:\n\n* Patients must be diagnosed with hematological neoplasms\n* Antineoplastic drugs or anti-infective drugs used as part of regular treatment\n\nExclusion Criteria:\n\n* expected survival time less than the treatment cycle;\n* patients with other factors that researcher considers unsuitable for inclusion.","ALL","1 Day","18 Years",{"count":111,"type":112},1500,"ESTIMATED","INTERVENTIONAL",[115],"PHASE4","The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.",[118],"Hematological Neoplasms","2025-03-25",{"date":121,"type":122},"2025-03-30","ACTUAL",{"date":124,"type":122},"2016-01-31",{"date":126,"type":112},"2026-12-31",{"name":96,"class":6},2]